- Home
- LUNG vs DMAC Comparison
LUNG vs DMAC Comparison
Compare LUNG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- DMAC
- Stock Information
- Founded
- LUNG 1995
- DMAC 2000
- Country
- LUNG United States
- DMAC United States
- Employees
- LUNG N/A
- DMAC N/A
- Industry
- LUNG Industrial Specialties
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- DMAC Health Care
- Exchange
- LUNG Nasdaq
- DMAC Nasdaq
- Market Cap
- LUNG 65.6M
- DMAC 310.1M
- IPO Year
- LUNG 2020
- DMAC N/A
- Fundamental
- Price
- LUNG $1.55
- DMAC $6.87
- Analyst Decision
- LUNG Buy
- DMAC Strong Buy
- Analyst Count
- LUNG 7
- DMAC 3
- Target Price
- LUNG $7.66
- DMAC $12.33
- AVG Volume (30 Days)
- LUNG 480.4K
- DMAC 448.5K
- Earning Date
- LUNG 10-29-2025
- DMAC 11-12-2025
- Dividend Yield
- LUNG N/A
- DMAC N/A
- EPS Growth
- LUNG N/A
- DMAC N/A
- EPS
- LUNG N/A
- DMAC N/A
- Revenue
- LUNG $90,549,000.00
- DMAC N/A
- Revenue This Year
- LUNG $10.30
- DMAC N/A
- Revenue Next Year
- LUNG $14.72
- DMAC N/A
- P/E Ratio
- LUNG N/A
- DMAC N/A
- Revenue Growth
- LUNG 18.24
- DMAC N/A
- 52 Week Low
- LUNG $1.47
- DMAC $3.19
- 52 Week High
- LUNG $9.37
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- LUNG 37.40
- DMAC 63.84
- Support Level
- LUNG $1.60
- DMAC $6.83
- Resistance Level
- LUNG $1.76
- DMAC $7.41
- Average True Range (ATR)
- LUNG 0.13
- DMAC 0.43
- MACD
- LUNG 0.02
- DMAC 0.03
- Stochastic Oscillator
- LUNG 2.86
- DMAC 73.62
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.